We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and
histone deacetylase 6 (HDAC6)-selective inhibitors (> 1 log unit difference versus class I …

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC)
has recently been validated as a potentially novel therapeutic approach for Alzheimer's …

Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone
deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing …

In order to determine the contributions of histone deacetylase (HDAC) isoforms to the
beneficial effects of dual phosphodiesterase 5 (PDE5) and pan-HDAC inhibitors on in vivo …

The discouraging results with therapies for Alzheimer's disease (AD) in clinical trials,
highlights the urgent need to adopt new approaches. Like other complex diseases, it is …

A novel systems therapeutics approach, involving simultaneous inhibition of
phosphodiesterase 5 (PDE5) and histone deacetylase (HDAC), has been validated as a …

The targeting of two independent but synergistic enzymatic activities, histone deacetylases
(HDACs, class I and HDAC6) and phosphodiesterase 5 (PDE5), has recently been validated …

Through drug discovery strategies of repurposing and redeveloping existing drugs, a series
of novel tadalafil derivatives were rationally designed, synthesized, and evaluated to seek …

Multitarget agents simultaneously trigger molecules in functionally complementary
pathways, and are therefore considered to have potential in effectively treating Alzheimer's …

Concomitant inhibition of butyrylcholinesterase (BChE) and histone deacetylase 6 (HDAC6)
is supposed to be effective in the treatment of Alzheimer's disease (AD). Inspired by our …